Deutsche Bank
TRDA icon

Deutsche Bank’s Entrada Therapeutics TRDA Stock Holding History

Deutsche Bank’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Buy
26,556
+1,877
+8% +$18K ﹤0.01% 3268
2026
Q1 		$311K Buy
24,679
+3,858
+19% +$44.2K ﹤0.01% 2812
2025
Q4 		$214K Sell
20,821
-187
-0.9% -$1.58K ﹤0.01% 2982
2025
Q3 		$122K Buy
21,008
+5,473
+35% +$32K ﹤0.01% 3271
2025
Q2 		$104K Sell
15,535
-3,969
-20% -$31.9K ﹤0.01% 3236
2025
Q1 		$176K Sell
19,504
-2,236
-10% -$27.9K ﹤0.01% 3012
2024
Q4 		$376K Buy
21,740
+7,757
+55% +$141K ﹤0.01% 2771
2024
Q3 		$223K Buy
13,983
+3,756
+37% +$59.2K ﹤0.01% 2881
2024
Q2 		$146K Buy
10,227
+118
+1% +$1.68K ﹤0.01% 2976
2024
Q1 		$143K Buy
10,109
+301
+3% +$4.26K ﹤0.01% 3006
2023
Q4 		$148K Sell
9,808
-230
-2% -$3.41K ﹤0.01% 3031
2023
Q3 		$159K Buy
10,038
+1,532
+18% +$24.1K ﹤0.01% 2923
2023
Q2 		$129K Buy
+8,506
New +$117K ﹤0.01% 3139
2022
Q2 		– Sell
-4,959
Closed -$47K – 4323
2022
Q1 		$47K Sell
4,959
-608
-11% -$6.52K ﹤0.01% 3864
2021
Q4 		$95K Buy
+5,567
New +$135K ﹤0.01% 3733

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Deutsche Bank's TRDA Position: Q2 2026 in Review

Deutsche Bank increased its Entrada Therapeutics (TRDA) stake by 7.6% in Q2 2026, buying an estimated $18K and bringing the position to 26,556 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3268.

Deutsche Bank first reported a position in TRDA in Q4 2021 and has held it in 15 quarters since. The position peaked at $376K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Deutsche Bank held 26,556 shares of Entrada Therapeutics worth $195K as of Q2 2026.
  • Deutsche Bank bought 1,877 Entrada Therapeutics shares in Q2 2026, an estimated $18K.
  • Entrada Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3268 holding.
  • Deutsche Bank first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Deutsche Bank's Entrada Therapeutics position peaked at $376K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.